Published in Nat Rev Urol on January 17, 2012
Visceral disease in castration-resistant prostate cancer. Eur Urol (2013) 1.23
Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer. PLoS One (2013) 1.04
The emerging role of histone lysine demethylases in prostate cancer. Mol Cancer (2012) 0.91
Complete regression of advanced prostate cancer for ten years: A case report and review of the literature. Oncol Lett (2013) 0.80
Regulation of Androgen Receptor by E3 Ubiquitin Ligases: for More or Less. Receptors Clin Investig (2014) 0.80
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (2011) 11.28
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32
Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell (2011) 4.43
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53
Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. Clin Cancer Res (2011) 1.64
Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers. Oncogene (2011) 1.20
Beyond hormone therapy for prostate cancer with PARP inhibitors. Cancer Cell (2011) 0.96
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol (2010) 5.86
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res (2012) 2.81
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol (2007) 2.79
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol (2012) 2.31
Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer (2014) 1.93
Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU Int (2008) 1.88
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res (2007) 1.87
Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol (2008) 1.85
Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res (2007) 1.84
Abiraterone acetate is well tolerated without concomitant use of corticosteroids. J Clin Oncol (2010) 1.51
CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol (2008) 1.49
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One (2012) 1.27
Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer. Clin Cancer Res (2013) 1.26
Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol (2013) 1.24
Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. Mod Pathol (2012) 1.19
Expression profiling of CD133+ and CD133- epithelial cells from human prostate. Prostate (2008) 1.11
Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer. PLoS One (2013) 1.04
Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival. PLoS One (2011) 1.03
The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer. Mol Cancer Ther (2012) 1.01
Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib. J Natl Cancer Inst (2014) 1.01
The CT flare response of metastatic bone disease in prostate cancer. Acta Radiol (2011) 0.99
Sarcomatoid carcinoma of the prostate: ERG fluorescence in-situ hybridization confirms epithelial origin. Histopathology (2014) 0.97
Beyond hormone therapy for prostate cancer with PARP inhibitors. Cancer Cell (2011) 0.96
Prostate cancer: PSA as an intermediate end point in clinical trials. Nat Rev Urol (2009) 0.92
Making sense of antisense. Eur J Cancer (2005) 0.91
Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials. Clin Cancer Res (2011) 0.91
Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer. Mol Cell Endocrinol (2011) 0.89
Studies of TMPRSS2-ERG gene fusions in diagnostic trans-rectal prostate biopsies. Clin Cancer Res (2010) 0.88
Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone. Cancer Treat Rev (2013) 0.87
Reporting the capture efficiency of a filter-based microdevice: a CTC is not a CTC unless it is CD45 negative--letter. Clin Cancer Res (2011) 0.87
The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. Eur Urol (2011) 0.85
Improved therapeutic targeting of the androgen receptor: rational drug design improves survival in castration-resistant prostate cancer. Curr Drug Targets (2013) 0.83
A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors. Clin Cancer Res (2009) 0.82
Novel strategies to test biological hypotheses in early drug development for advanced prostate cancer. Clin Chem (2012) 0.81
A step toward functionally characterized prostate cancer molecular subtypes. Nat Med (2013) 0.80
Identifying prognostic signatures in the blood of ovarian cancer patients. Gynecol Oncol (2013) 0.77
Advances in the management of high-risk localised and metastatic prostate cancer. BJU Int (2012) 0.76
New prostate cancer drug: Prostate cancer's day in the sun. BMJ (2008) 0.75
Integrative Clinical Genomics of Advanced Prostate Cancer. Cell (2015) 0.75